Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE: dostarlimab sequential therapy after chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma
CTR20243523Phase 3Active
- Sponsor
- GSK
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dostarlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by GSK. Started Feb 2025; status: active.
02
Drugs
dostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20243523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243523.